

Akronym/Firma	Substanz	Phase	Indikation	Beschreibung	Rekrutierung
<u>IPF und PF-ILD STUDIEN</u>					
CADPT / Novartis	CADPT09A12201	II	Idiopathische Lungenfibrose	A participant- and investigator-blinded, randomized, placebo-controlled, multicenter, platform study to investigate efficacy, safety, and tolerability of various single treatments in participants with idiopathic pulmonary fibrosis	Aktiv
INSMED/ Insmed Incorporated	INS1009-212 (Treprostinil Palmitil)	II	PF-ILD	A Phase 2, Randomized, Double-Blind, Multicenter, Placebo Controlled Study to Evaluate the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease.	Abgeschlossen
FIBRONEER/ Boehringer-Ingelheim	BI 1015550	III	Idiopathische Lungenfibrose / PF-ILD	A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over 53'2 weeks in patients with IPF / Progressive Fibrosing Interstitial Lung Disease (PF-ILD).	Abgeschlossen
Modern IST 07 / Modern Biosciences	MBS2320	II	Idiopathische Lungenfibrose	A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Investigate the Efficacy and Safety of MBS2320 in Patients With Idiopathic Pulmonary Fibrosis	Aktiv
RIN-PF 303 / United Therapeutics	Inhaled Treprostinil	III	Idiopathische Lungenfibrose	A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with Idiopathic Pulmonary Fibrosis (TETON-2)	Aktiv

Moonscape GB 44496 / Genentech	Vixarelimab	II	Idiopathische Lungenfibrose / SSc-ILD	A two-cohort, Phase II, multicenter, randomized, double-blind, parallel-group, placebo-controlled study evaluating the efficacy and safety of vixarelimab compared with placebo in patients with idiopathic pulmonary fibrosis and in patients with systemic sclerosis-associated interstitial lung disease.	Aktiv
Coral NAL 03-202 / Trevi Therapeutics	Nalbuphine	IIb	Idiopathische Lungenfibrose	A Randomized, Double-Blind, Placebo-Controlled, Parallel, 4-Arm Dose Ranging Study of the Safety and Efficacy of Nalbuphine Extended-Release Tablets (NAL ER) for the Treatment of Cough in Idiopathic Pulmonary Fibrosis (IPF).	Aktiv
Tefibeos / Astra Zeneca	Tezepelumab	II	PF-ILD	A prospective two-armed, phase II clinical multicentre randomized, placebocontrolled (2:1), blinded with open-label extension	Aktiv
IM027068 / IM0271015 Bristol Myers Squibb Company	BMS-986278	III	Idiopathische Lungenfibrose / PPF	A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis / A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis	In Vorbereitung
Beacon IPF / Pliant	Bexotegrast	IIb	Idiopathische Lungenfibrose	A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF)	In Vorbereitung
Fibroner-On / Boehringer-Ingelheim	Nerandomilast	IV	Idiopathische Lungenfibrose / PF-ILD	An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER™-ON)	In Vorbereitung
Transform 220929 / Glaxo Smith Kline	GSK3915393	II	Idiopathische Lungenfibrose	A Phase 2, randomized, double-blind, placebo-controlled, parallel group study (TRANSFORM) to evaluate the efficacy and safety of GSK3915393 in participants with Idiopathic Pulmonary Fibrosis (IPF)	In Vorbereitung

BEconneCTD-ILD 221672 / Glaxo Smith Kline	GSK1550188	III	CTD-ILD	A Phase 3, randomized, double-blind, placebocontrolled, parallel group study to evaluate the efficacy and safety of belimumab administered subcutaneously in adults with interstitial lung disease (ILD) asso	In Vorberietung
<u>Alveolar Proteinose STUDIEN</u>					
IMPALA 2/ Savara	Molgramostin (GM-CSF inhalativ)	III	Alveolar Proteinose	A randomized, Double Blind, Placebo-controlled Clinical trial of once-daily inhaled Molgramostim nebulizer solution in adult subjects with autoimmune Alveolar-Proteinosis (aPAP).	Abgeschlossen
<u>Sarkoidose STUDIEN</u>					
ATYR1923-C-004 / Atyr Pharma	Efzofitimod	III	Sarkoidose	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis.	Aktiv
<u>Beobachtungsstudien / Registerstudien</u>					
Insight-ILD / Boehringer-Ingelheim / GWD	INSIGHTS-ILD Register	NA	Idiopathische Lungenfibrose	INvestigating SIGNificant Health Trends in Progressive Fibrosing Interstitial Lung Disease	Aktiv